Carfilzomib

Research use only, not for human use.

A potent, highly selective inhibitor chymotrypsin-like activity of proteasome with IC50 of 6 nM.

A potent, highly selective inhibitor chymotrypsin-like activity of proteasome with IC50 of 6 nM; weakly inhibits caspase-like and trypsin-like activities in cellular assays (IC50150-200 nM), also inhibits the chymotrypsin-like activity of the immunoproteasome (IC50=33 nM); accumulates proteasome substrates and induces cell cycle arrest and/or apoptosis; shows antitumor efficacy in vivo.Blood Cancer Approved.

——

——

PR 171 | PR171 | PR-171

Proteasome/Ubiquitin

Proteasome

Proteasome

Cancer

Blood cancer

868540-17-4

719.9099

C40H57N5O7

>98% (HPLC)

10 mM in DMSO

CC(C)C[C@H](NC([C@@H](NC(CN1CCOCC1)=O)CCC2=CC=CC=C2)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC(C)C)C([C@]4(C)OC4)=O)=O)=O.

L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-

(-20℃)

With Ice Pack

≥ 2 years